Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share.
The offer of $402 per share was made in connection with Abbott's acquisition of Alere, which was completed on Tuesday.
Abbott's tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at $402 per share is now scheduled to expire on Oct. 3.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Agilent received notice of an unsolicited mini-tender offer by TRC Capital to purchase up to 2.5 million shares of Agilent's shares at a discount to market price.
Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock.
Roche said that based on preliminary results, Foundation Medicine shareholders tendered a total of 17.5 million shares, not including 1.9 million shares that were tendered by notice of guaranteed delivery.
Roche will acquire a majority stake in Foundation Medicine and directly invest in R&D.
The offer for 15.6 million shares of Foundation's common stock at $50 per share has been extended to midnight EST at the end of the day April 6.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.